S S Negus, M R Brandt, N K Mello
Index: J. Pharmacol. Exp. Ther. 291 , 60-69, (1999)
Full Text: HTML
Cocaine is a nonselective monoamine reuptake inhibitor that is widely abused. Useful pharmacotherapies for cocaine dependence may include substitution medications that produce cocaine-like effects but have a slower onset and longer duration of action. Accordingly, the present study examined the effects of the long-acting, nonselective monoamine reuptake inhibitor indatraline in assays of cocaine discrimination and cocaine self-administration that have been used to evaluate other candidate treatment medications. In rhesus monkeys trained to discriminate cocaine (0.4 mg/kg) from saline, indatraline (0.1-1.0 mg/kg) produced a dose- and time-dependent substitution for cocaine. The effects of 1.0 mg/kg indatraline peaked after 30 min and lasted up to 24 h. In monkeys trained to self-administer 0.032 mg/kg/injection cocaine and food pellets during alternating daily sessions of cocaine and food availability, indatraline (0.0032-0.032 mg/kg/injection) maintained lower rates of responding than cocaine. Repeated treatments with indatraline (0.1-0.56 mg/kg/day) for 7 days produced dose-dependent and sustained decreases in cocaine self-administration across a broad range of cocaine doses (0.0032-0.1 mg/kg/injection), and the highest dose of indatraline (0.56 mg/kg/day) nearly eliminated cocaine-maintained responding. However, doses of indatraline that decreased cocaine self-administration also usually decreased rates of food-maintained responding and produced behavioral stereotypies and trends toward weight loss and mild anemia. These findings suggest that although indatraline may decrease cocaine-taking behavior in rhesus monkeys, it also produces undesirable side effects that may limit its clinical utility in the treatment of cocaine dependence.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
Indatraline hydrochloride
CAS:96850-13-4 |
C16H16Cl3N |
Neurochemical profile of Lu 19-005, a potent inhibitor of up...
1985-05-01 [J. Neurochem. 44 , 1615-1622, (1985)] |
Pharmacology in vivo of the phenylindan derivative, Lu 19-00...
1985-04-01 [Naunyn Schmiedebergs Arch. Pharmacol. 329 , 101-107, (1985)] |
Down-regulation of dopamine D-2, 5-HT2 receptors and beta-ad...
[J. Neural Transm. Gen. Sect. 64 , 227-238, (1985)] |
In vivo neurochemical profile of dopamine uptake inhibitors ...
1989-07-18 [Eur. J. Pharmacol. 166(2) , 251-60, (1989)] |
Ca2+ dependence of the amphetamine, nomifensine, and Lu 19-0...
1989-07-18 [Eur. J. Pharmacol. 166(2) , 261-9, (1989)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved